JP2003506024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506024A5 JP2003506024A5 JP2001513966A JP2001513966A JP2003506024A5 JP 2003506024 A5 JP2003506024 A5 JP 2003506024A5 JP 2001513966 A JP2001513966 A JP 2001513966A JP 2001513966 A JP2001513966 A JP 2001513966A JP 2003506024 A5 JP2003506024 A5 JP 2003506024A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- hgf
- acid ligand
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 239000003446 ligand Substances 0.000 description 20
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 17
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 16
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- JCAQMQLAHNGVPY-UUOKFMHZSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(2,2,4-trioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-7-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical class O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 JCAQMQLAHNGVPY-UUOKFMHZSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53642890A | 1990-06-11 | 1990-06-11 | |
| US09/364,539 | 1999-07-29 | ||
| US09/364,539 US6344321B1 (en) | 1990-06-11 | 1999-07-29 | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| US09/364,543 US6331394B1 (en) | 1991-06-10 | 1999-07-29 | Nucleic acid ligands to integrins |
| US09/364,543 | 1999-07-29 | ||
| PCT/US2000/020139 WO2001009159A1 (en) | 1990-06-11 | 2000-07-24 | Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003506024A JP2003506024A (ja) | 2003-02-18 |
| JP2003506024A5 true JP2003506024A5 (https=) | 2007-09-13 |
Family
ID=48986297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513966A Pending JP2003506024A (ja) | 1990-06-11 | 2000-07-24 | 肝細胞増殖因子／細胞分散因子（ＨＧＦ）又はその受容体ｃ−ｍｅｔ、及びインテグリン類に対する核酸リガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6344321B1 (https=) |
| EP (1) | EP1203007B1 (https=) |
| JP (1) | JP2003506024A (https=) |
| CA (1) | CA2381004A1 (https=) |
| WO (1) | WO2001009159A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166741A1 (en) * | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| CA2328356A1 (en) * | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| US7312325B2 (en) * | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
| US20030118585A1 (en) | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
| DK2070939T3 (da) | 2001-05-25 | 2014-06-23 | Univ Duke | Modulatorer af farmakologiske midler |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| DK2280070T3 (en) | 2001-07-23 | 2015-08-24 | Univ Leland Stanford Junior | Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals |
| US7435542B2 (en) * | 2002-06-24 | 2008-10-14 | Cornell Research Foundation, Inc. | Exhaustive selection of RNA aptamers against complex targets |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US7670631B2 (en) * | 2003-03-12 | 2010-03-02 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists |
| JP2007525177A (ja) * | 2003-04-21 | 2007-09-06 | アーケミックス コーポレイション | 血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用 |
| WO2005001486A1 (en) * | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US20050123932A1 (en) * | 2003-12-09 | 2005-06-09 | Mekbib Astatke | Nucleic acid-chelating agent conjugates |
| WO2005086835A2 (en) * | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics |
| US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| US20050260153A1 (en) * | 2004-04-13 | 2005-11-24 | Pericles Calias | Facilitation of iontophoresis using charged moieties |
| US7989613B2 (en) * | 2004-10-19 | 2011-08-02 | Texas Tech University | Inhibition of metallo-β-lactamase by RNA |
| CA2614145A1 (en) * | 2005-07-05 | 2007-01-11 | Ribomic Inc. | Nucleic acid capable of binding to immunoglobulin g and use thereof |
| JP4910195B2 (ja) * | 2005-07-05 | 2012-04-04 | 株式会社リボミック | 免疫グロブリンｇに結合する核酸とその利用法 |
| CA2634987C (en) * | 2006-01-17 | 2017-01-03 | Somalogic, Inc. | Multiplexed analyses of test samples |
| JP4698559B2 (ja) | 2006-11-24 | 2011-06-08 | Ｎｅｃソフト株式会社 | ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子 |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| CN102112490B (zh) | 2008-07-08 | 2014-10-22 | 昂考梅德药品有限公司 | Notch1受体结合剂和其使用方法 |
| CN102459298A (zh) * | 2009-05-05 | 2012-05-16 | 阿尔特姆恩科技责任有限公司 | 化学可编程免疫 |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| US8236570B2 (en) * | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| EP2535410A4 (en) | 2010-02-12 | 2014-08-13 | Ribomic Inc | APTAMER FOR FGF2 AND USE THEREOF |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| WO2011125458A1 (ja) | 2010-04-02 | 2011-10-13 | 富士レビオ株式会社 | 抗癌剤の効果の診断用マーカー |
| JPWO2012014890A1 (ja) * | 2010-07-26 | 2013-09-12 | Ｎｅｃソフト株式会社 | ｃ−Ｍｅｔ結合核酸分子およびその用途 |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| EP2648765A1 (en) * | 2010-12-10 | 2013-10-16 | Merck Patent GmbH | Aptamer labeled with f-19 nucleus for targeted molecular imaging by mri |
| US20140301989A1 (en) * | 2011-06-17 | 2014-10-09 | Brian Johnstone | Methods for increasing the potency and efficacy of stem cells |
| GB201114662D0 (en) | 2011-08-24 | 2011-10-12 | Altermune Technologies Llc | Chemically programmable immunity |
| KR20180128097A (ko) * | 2012-02-10 | 2018-11-30 | 재패닉 코포레이션 | 비 인간 줄기세포의 배양 상등액을 원료로 하는 화장품 또는 피부 재생 촉진제, 및 단백질의 이온 도입 방법 |
| WO2013155686A1 (zh) * | 2012-04-18 | 2013-10-24 | Wang Lemin | 整合素β亚基在诊断静脉血栓栓塞中的应用 |
| CN104388422B (zh) * | 2014-10-24 | 2017-08-25 | 集美大学 | 寡核苷酸序列及其制备方法与应用 |
| KR20200068647A (ko) * | 2017-08-11 | 2020-06-15 | 시티 오브 호프 | 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머 |
| PE20211959A1 (es) | 2019-02-15 | 2021-09-30 | Editas Medicine Inc | Celulas asesinas naturales (nk) modificadas para inmunoterapia |
| CN114853869B (zh) * | 2019-12-10 | 2023-12-26 | 湖南赛奥维生物技术有限公司 | 一种碱性成纤维细胞生长因子替代物及其组合物和应用 |
| EP4232567A1 (en) | 2020-10-26 | 2023-08-30 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| CN117479952A (zh) | 2021-04-07 | 2024-01-30 | 世纪治疗股份有限公司 | 用于嵌合抗原受体细胞的组合的人工细胞死亡/报告系统多肽及其用途 |
| WO2022216624A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| BR112023018844A2 (pt) | 2021-04-07 | 2023-10-10 | Century Therapeutics Inc | Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas |
| EP4359541A4 (en) | 2021-06-23 | 2025-04-30 | Editas Medicine, Inc. | Engineered cells for therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5683867A (en) * | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| ES2259800T3 (es) * | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5874218A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| US5837834A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
| US5731424A (en) * | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US5472841A (en) * | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
| JPH06508022A (ja) | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ，インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
| CA2102595C (en) * | 1991-05-10 | 2003-01-14 | Paolo Comoglio | Truncated forms of the hepatocyte growth factor (hgf) receptor |
| US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| ATE160585T1 (de) * | 1992-09-18 | 1997-12-15 | Us Gov Health & Human Serv | Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie |
| JPH09502354A (ja) * | 1993-09-08 | 1997-03-11 | ネクスター ファーマスーティカルズ，インコーポレイテッド | 核酸リガンドと、同リガンドを製造するための改良された方法 |
| JP4531132B2 (ja) * | 1995-06-02 | 2010-08-25 | ギリード・サイエンシズ・インコーポレーテッド | 増殖因子に対する高親和性オリゴヌクレオチドリガンド |
-
1999
- 1999-07-29 US US09/364,539 patent/US6344321B1/en not_active Expired - Fee Related
-
2000
- 2000-07-24 EP EP00948923A patent/EP1203007B1/en not_active Expired - Lifetime
- 2000-07-24 CA CA002381004A patent/CA2381004A1/en not_active Abandoned
- 2000-07-24 WO PCT/US2000/020139 patent/WO2001009159A1/en not_active Ceased
- 2000-07-24 JP JP2001513966A patent/JP2003506024A/ja active Pending
-
2006
- 2006-08-22 US US11/508,024 patent/US20070010473A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506024A5 (https=) | ||
| JP2004511201A5 (https=) | ||
| DE3049831C2 (de) | Vektoren enthaltend eine f}r das Oberfl{chenantigen des Hepatites B-Virus kodierende Nucleotidsequenz, Verwendung dieser Vektoren zur Herstellung von Peptiden, Impfstoffe enhaltend dabei erhaltende Peptide als Antigen | |
| JP2002535015A5 (https=) | ||
| WO2005021707A3 (en) | Severe acute respiratory syndrome dna vaccine compositions and methods of use | |
| JP2002541233A5 (https=) | ||
| Ulrich et al. | Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury | |
| JP2011530599A5 (https=) | ||
| DE59913833D1 (de) | Strukturprotein von aav, seine herstellung und verwendung | |
| WO2005055948A3 (en) | Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders | |
| AU7194101A (en) | Treatment of glycogen storage disease type ii | |
| JP2003505111A5 (https=) | ||
| Jouet et al. | Exon 2 of the gene for neural cell adhesion molecule Ll is alternatively spliced in B cells | |
| ATE238321T1 (de) | Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung | |
| Zhang et al. | Skin tumorigenesis and Ki‐ras and Ha‐ras mutations in tumors from adult mice exposed in utero to 3′‐azido‐2′, 3′‐dideoxythymidine | |
| JP2023521361A5 (https=) | ||
| CN108210510A (zh) | 一种小干扰核酸药物组合物及其用途 | |
| JP2004201692A5 (https=) | ||
| ATE325874T1 (de) | Cd154 varianten und deren verwendung | |
| McMahon et al. | Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels | |
| WO2001051489A3 (en) | Methods for lowering uric acid levels | |
| IE892640L (en) | Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders | |
| RU2215787C2 (ru) | АКТИН-РЕЗИСТЕНТНЫЙ ВАРИАНТ ДНКазы I (ВАРИАНТЫ), ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, СПОСОБ СНИЖЕНИЯ ВЯЗКОУПРУГОСТИ ИЛИ ВЯЗКОЙ КОНСИСТЕНТНОСТИ МОКРОТЫ ПАЦИЕНТА | |
| CA2701521C (en) | Use of the sequence encoding of the carboxyl-terminal domain of the heavy chain of the tetanus toxin as a drug | |
| JP2024527525A5 (https=) |